Title | New Therapeutics and Delivery Systems on the Horizon |
Purpose | Reduction of the intraocular pressure in glaucoma is usually by using eye drops. This delivery method is pulsatile and have multiple limitations. Next to the drug-dependent bioavailability problems, there are various patient- dependent issues, and a true control of the doses of the delivered medication is very difficult. Therefore the real efficacy of the treatment is in each patient different. |
Methods | There is a need for novel delivery systems to address the issue of ocular surface disease, compliance and adherence to ensure consistent reduction of IOP. These delivery systems include contact lenses-releasing glaucoma medications, injectables such as biodegradable micro- and nanoparticles, and surgically implanted systems. These new technologies are aimed at increasing clinical efficacy by offering multiple delivery options and are capable of managing IOP for several months. |
Results | Most of these new delivery systems are in research or fase III studies. The long-term results are unkwon. |
Conclusion | Interesting session to catch-up with new technoloies in drug delivery. |
Conflict of interest | Yes |
Details of conflicting interests | Consultant for EyeD Pharma |
Last name | POURJAVAN |
Initials | S |
Department | Chirec Hospitals, site Delta |
City | Brussels |